J.P. Morgan Chase & Co. discusses Charles River Laboratories CRL in a research report after the company reported earnings. It has a Neutral rating on shares and a $34 price target.
In a note to clients, J.P. Morgan writes, "Bottom-line result due largely to share repurchase. Under the accelerated share repurchase and prior program, the company repurchased 8.55M shares of stock in the quarter. The board has authorized an incremental $250M in share repurchase. Guidance cut. CRL reduced its guidance from $1.90-$2.00 to $1.85-1.90, now expecting -5% revenue growth in 2010 (vs prior 2-3% decrease), and sequentially flat revenues in Q4."
Shares of CRL lost 1 cent yesterday to close at $32.92.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CareJ.P. Morgan Chase & Co.Life Sciences Tools & Services
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in